Application Note: Metabolite Identification of Payload Species of Antibody Drug Conjugates with Noncleavable Linkers using MetabolitePilot™ 2.0 Software and TripleTOF® 6600 System
8 June 2017
Antibody drug conjugates (ADC) are designed for targeted delivery of a cytotoxic molecule to a diseased or cancerous tissue. The goal in design and development of ADCs is to maximize delivery to the targeted tissue and minimize delivery to untargeted tissues. There are currently two FDA approved ADC therapies on the market for the treatment of cancer and research efforts in ADC technology have grown across the pharmaceutical industry to encompass therapeutic areas other than cancer. Sciex has introduced a number of technologies, highlighted in this technical note, to aid in the discovery of ADCs.